Shares of Consort Medical plc (LON:CSRT) have been given a consensus recommendation of “Buy” by the seven research firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is GBX 1,178.17 ($15.50).

Separately, Stifel Nicolaus restated a “buy” rating and issued a GBX 1,250 ($16.44) price objective on shares of Consort Medical plc in a research note on Thursday, November 9th.

TRADEMARK VIOLATION WARNING: This story was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at

Shares of Consort Medical plc (LON:CSRT) traded down GBX 9 ($0.12) on Thursday, reaching GBX 1,091 ($14.35). 8,127 shares of the company’s stock were exchanged, compared to its average volume of 32,247. Consort Medical plc has a 1-year low of GBX 960 ($12.63) and a 1-year high of GBX 1,129 ($14.85).

Consort Medical plc Company Profile

Consort Medical PLC is a contract development and manufacturing organization (CDMO). The Company’s principal activities include designing, development and manufacture of medical drug delivery devices and services for the pharmaceutical industry. The Company operates through two segments: Bespak and Aesica.

Analyst Recommendations for Consort Medical plc (LON:CSRT)

Receive News & Ratings for Consort Medical plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Consort Medical plc and related companies with Analyst Ratings Network's FREE daily email newsletter.